DEAN SPARKS: Open Payments
NPI 1952312217 · RATHDRUM, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$832 in 33 payments from 13 companies in 2025. Trend: 2023 $392 · 2024 $339 · 2025 $832
Food & beverage: $832
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $217 |
| Novo Nordisk Inc | 5 | $192 |
| PFIZER INC. | 5 | $121 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $48 |
| GlaxoSmithKline, LLC. | 2 | $44 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $44 |
| Phathom Pharmaceuticals, Inc. | 2 | $37 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $25 |
| Edwards Lifesciences Corporation | 1 | $24 |
| Boston Scientific Corporation | 1 | $24 |
Products named: Wegovy, UBRELVY, NURTEC ODT, QULIPTA, CAPLYTA, TRELEGY ELLIPTA, JOURNAVX, VOQUEZNA.
Industry payments across ID — which companies pay providers there.
